Georg Kunz
Bottrop, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 10, 2025
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 07, 2022
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 02, 2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 22, 2020
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 16, 2018
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Journal: Breast cancer research and treatment
Published: January 20, 2017
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 29, 2015
The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.
Journal: Deutsches Arzteblatt international
Published: March 07, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Journal: International journal of cancer
Published: October 20, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 17, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
Journal: Annals of surgical oncology
Published: November 06, 2013
Last Updated: 09/26/2026